Abzena (ABZA:AIM) has raised £25m to fund several growth initiatives, which include upgrading its US biomanufacturing facilities so it can supply more products.

Approximately £11m will be spent on its San Diego facility while £6m will be earmarked to enhance its biology and chemistry offering in the UK and US. The remaining £8m will be used for working capital.